Cell Therapy Market Analysis and Reports | UK Conference Series

Market Analysis - Cell Therapy 2018

Conference Series Ltd is overwhelmed and delighted to announce the inception of the novel event “7th International Conference on Cell and Gene Therapy.” The most awaited event would be staged during “March 15-17, 2018” at London, UK. With the theme upholding “Exploring the novel research and innovations in Cell & gene therapy”, the event is assured to bring forth transparent and significant changes in the Cell and Gene therapies which includes prompt keynote presentations, Oral talks, Poster presentations and Exhibitions

Cell Therapy conferences are the premier conference to gather scholars from all over the world to present advances in the relevant fields and to foster an environment conducive to exchanging ideas and information. This conference will also provide an ideal environment to develop new collaborations and meet experts on the fundamentals, applications, and products of the Advanced Gene Therapeutics. Cell therapy warmly welcomes Professors, Industrialists, Research scholars, CEO’s, and other experts related to the current field.

Importance & Scope:

Scope: The Scope of the conference is to gather all the Doctors, Researchers, Business Delegates and Scientists to approach and deliver all the attendees about the latest scientific advancements on the respective sphere. This Cell and Gene Therapy Conference is the premier event focusing on understanding individual and organizational behaviour and decision-making related to genetics and molecular biology, biotechnology, pharmaceuticals, medicals and academia.

Importance: Conference on Cell & Gene Therapy is a much celebrated conference which basically deals with the latest research and developments in the sphere of Cell and molecular biology. This Conference will provide a perfect platform to all the International mix of leading Research Scholars, and Scientists achieved eminence in their field of study, research academicians from the universities and research institutions, industrial research professionals and business associates along with Ph.D. Students to come and inform all the attendees about the latest scientific advancements on the respective sphere.


Top Major Societies Associated with Cell and Gene Therapy

  • British Society and Gene and Cell Therapy
  • American Society of Gene and Cell Therapy (ASGCT)
  • Australasian Gene Therapy Society (AGTS)
  • Austrian Network for Gene Therapy
  • British Society of Gene Therapy (BSGT)
  • European Society of Gene and Cell Therapy (ESGCT)
  • Finnish Gene Therapy Society (FGTS)
  • German Gene Therapy Society (DGGT)
  • International Society for Cancer Gene Therapy (ISCGT)
  • Irish Society for Gene & Cell Therapy (ISGCT)
  • Israeli Society of Gene & Cell Therapy (ISGCT)
  • Japan Society of Gene Therapy (JSGT)
  • Korean Society of Gene and Cell Therapy (KSGCT)
  • Netherlands Society of Gene and Cell Therapy (NVGCT)
  • Société Francophone de ThérapieCellulaire et  Génique (SFTCG)
  • Spanish Society of Gene and Cell Therapy (SETGyC)
  • Swedish Society for Gene and Cell Therapy (SSGCT)
  • Turkish Society of Gene & Cell Therapy (TSGCT)

Figure: Industries Associated with Cellular Therapies


Top Research Institutes of Cell and Gene Therapy Globally

Figure: List of Research Institutes


Market Value on Cell and Gene Therapy:

The global stem cell therapy market is expected to reach $330 million by 2020, at a CAGR of 39.5% from 2015 to 2020

The global stem cell market in 2015is expected to be dominated by North America, followed by Asia-Pacific and Europe. However, Asia-Pacific market is expected to surpass North America by 2020, owing to the high number of ongoing research activities.

Autologous Stem Cell and Non-Stem Cell Based Therapies market is currently estimated as $650 million, including products of all application areas. This market is anticipated to reach $2.2 billion by 2017, growing at a CAGR of 21%. ACT has already been successful in the treatment of prostate cancer, skin burns, cosmetic surgeries, skin substitutes, wound healing, pressure ulcers, etc.

Autologous Stem Cell and Non-Stem Cell Based Therapies Market, Revenue Forecast

Figure: Market Value

The markets for gene therapy are difficult to estimate as there is only one approved gene therapy product and it is marketed in China since 2004. Gene therapy markets are estimated for the years 2014-2024. The estimates are based on epidemiology of diseases to be treated with gene therapy, the portion of those who will be eligible for these treatments, competing technologies and the technical developments anticipated in the next decades.

Products manufactured by the industry related cell therapy and its market Value:

Global markets for stem cells by BCC Research (2012), cited by Ministry of Food and Drug Safety, predicted the global market size of stem cell therapy product would be 6.6 billion dollars in 2016 and grow 11.7% on average every year. Currently, US's stem cell therapy product occupying the biggest market share amounts to 1.3 billion dollars and Europe's is 872 million dollars. US's stem cell therapy product market is predicted to have an average annual growth rate of 11.5% (2.3 billion dollars in 2016), and Europe's is 10.9% (1.5 billion dollars in 2016). Until August 1, 2013, three stem cell therapies has acquired a sale permit for domestic use in Korea: Hearticellgram-AMI by FCB-Phamicell (the world's first stem cell therapy product), Cartistem by Medipost (the world's first allogenous stem cell therapy product) and Cupistem by Anterogen. Besides, 24 medicines are undergoing clinical trial till January 1, 2013.

Global markets for stem cells therapy product

Figure: Fund Allotment to Cell and Gene Therapy

US$3 billion state taxpayer-funded institute for stem cell research, the California Institute for Regenerative Medicine. It hopes to provide $300 million a year. However, in June 6, 2006, there were delays in the implementation of the California program and it is believed that the delays will continue for the significant future.  On July 21, 2006, Governor Arnold Schwarzenegger (R-Calif.) authorized $150 million in loans to the Institute in an attempt to jump start the process of funding research.

Semma Therapeutics, a company developing a cell therapy for Type 1 diabetes, announced today that it has closed a $44 million Series A consisting of equity financing and strategic funding. The Series A financing is led by MPM Capital, with Fidelity Biosciences, ARCH Venture Partners, and Medtronic participating. Alongside the equity financing, Semma entered into an undisclosed agreement with Novartis Pharmaceuticals.

NIH provided US$ 258 Million in funding for three SF universities, and US$ 41 Million to SF start up firms through Small Business Innovation Research grant scheme